338 related articles for article (PubMed ID: 20353989)
1. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis.
Rand JH; Wu XX; Quinn AS; Taatjes DJ
Lupus; 2010 Apr; 19(4):460-9. PubMed ID: 20353989
[TBL] [Abstract][Full Text] [Related]
2. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome.
Rand JH; Wu XX; Quinn AS; Taatjes DJ
Lupus; 2008 Oct; 17(10):922-30. PubMed ID: 18827057
[TBL] [Abstract][Full Text] [Related]
3. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome.
Rand JH
J Autoimmun; 2000 Sep; 15(2):107-11. PubMed ID: 10968894
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism.
Rand JH; Wu XX; Andree HA; Lockwood CJ; Guller S; Scher J; Harpel PC
N Engl J Med; 1997 Jul; 337(3):154-60. PubMed ID: 9219701
[TBL] [Abstract][Full Text] [Related]
5. [Antiphospholipid antibodies and recurrent abortions: possible pathogenetic role of annexin A5 investigated by confocal microscopy].
Peluso G; Morrone G
Minerva Ginecol; 2007 Jun; 59(3):223-9. PubMed ID: 17576401
[TBL] [Abstract][Full Text] [Related]
6. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view.
Meroni PL; Tedesco F; Locati M; Vecchi A; Di Simone N; Acaia B; Pierangeli SS; Borghi MO
Lupus; 2010 Apr; 19(4):453-6. PubMed ID: 20353987
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.
Rand JH; Wu XX; Quinn AS; Chen PP; McCrae KR; Bovill EG; Taatjes DJ
Am J Pathol; 2003 Sep; 163(3):1193-200. PubMed ID: 12937161
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.
Rand JH; Wu XX; Quinn AS; Ashton AW; Chen PP; Hathcock JJ; Andree HA; Taatjes DJ
Blood; 2010 Mar; 115(11):2292-9. PubMed ID: 19965621
[TBL] [Abstract][Full Text] [Related]
9. Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes.
Frank M; Sodin-Semrl S; Irman S; Bozic B; Rozman B
Autoimmun Rev; 2009 Sep; 9(1):5-10. PubMed ID: 19232551
[TBL] [Abstract][Full Text] [Related]
10. Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease.
Frostegård AG; Su J; von Landenberg P; Frostegård J
Scand J Rheumatol; 2010; 39(1):77-83. PubMed ID: 20132075
[TBL] [Abstract][Full Text] [Related]
11. Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes.
Wolgast LR; Arslan AA; Wu XX; Beyda JN; Pengo V; Rand JH
J Thromb Haemost; 2017 Jul; 15(7):1412-1421. PubMed ID: 28393472
[TBL] [Abstract][Full Text] [Related]
12. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
13. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.
Pierangeli SS; Chen PP; Raschi E; Scurati S; Grossi C; Borghi MO; Palomo I; Harris EN; Meroni PL
Semin Thromb Hemost; 2008 Apr; 34(3):236-50. PubMed ID: 18720303
[TBL] [Abstract][Full Text] [Related]
14. Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-beta2-glycoprotein I and anti-annexin A5 antibodies.
Gaspersic N; Ambrozic A; Bozic B; Majhenc J; Svetina S; Rozman B
Rheumatology (Oxford); 2007 Jan; 46(1):81-6. PubMed ID: 16820381
[TBL] [Abstract][Full Text] [Related]
15. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome.
Rand JH; Wu XX; Lapinski R; van Heerde WL; Reutelingsperger CP; Chen PP; Ortel TL
Blood; 2004 Nov; 104(9):2783-90. PubMed ID: 15242878
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against annexin A5: detection pitfalls and clinical associations.
Bozic B; Irman S; Gaspersic N; Kveder T; Rozman B
Autoimmunity; 2005 Sep; 38(6):425-30. PubMed ID: 16278147
[TBL] [Abstract][Full Text] [Related]
17. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins.
Bertolaccini ML; Hughes GR; Khamashta MA
Clin Lab; 2004; 50(11-12):653-65. PubMed ID: 15575307
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin.
Di Simone N; Meroni PL; D'Asta M; Di Nicuolo F; D'Alessio MC; Caruso A
Hum Reprod Update; 2007; 13(2):189-96. PubMed ID: 17099207
[TBL] [Abstract][Full Text] [Related]
19. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.
de Laat B; Wu XX; van Lummel M; Derksen RH; de Groot PG; Rand JH
Blood; 2007 Feb; 109(4):1490-4. PubMed ID: 17053060
[TBL] [Abstract][Full Text] [Related]
20. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment.
Asherson RA; Cervera R; Merrill JT; Erkan D
Semin Thromb Hemost; 2008 Apr; 34(3):256-66. PubMed ID: 18720305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
